Lucid Diagnostics Inc (NAS:LUCD)
$ 1.065 +0.050 (+4.85%) Market Cap: 203.17 Mil Enterprise Value: 215.10 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 26/100

Q4 2025 Lucid Diagnostics Inc Earnings Call Transcript

Mar 26, 2026 / 12:30PM GMT
Release Date Price: $1.15 (-3.36%)

Key Points

Positve
  • Lucid Diagnostics Inc (LUCD) reported a 29% increase in test volume for the fourth quarter, exceeding their target range.
  • The company achieved a significant milestone by securing a contract with the US Department of Veteran Affairs, which could potentially expand their market reach.
  • Positive data from the largest reported real-world experience of esophageal pre-cancer testing was announced, demonstrating the effectiveness and safety of their EsoGuard and EsoCheck tests.
  • Lucid Diagnostics Inc (LUCD) is making progress in securing coverage with major payers like UnitedHealthcare, which could lead to increased revenue.
  • The company is strategically reallocating resources to focus on Medicare and VA populations, which are expected to drive future growth.
Negative
  • Lucid Diagnostics Inc (LUCD) is still awaiting Medicare coverage, which is crucial for their revenue recognition and growth.
  • The company faces challenges with revenue recognition due to the transitional stages of their reimbursement process.
  • Operating expenses increased due to investments in sales and market access staffing, impacting their financials.
  • There is a delay in the publication of the draft LCD for Medicare, affecting their ability to collect payments for past services.
  • The company is cautious about increasing their sales team and operational expenses due to the current capital markets environment.
Operator

Good morning and welcome to the Lucid Diagnostics fourth quarter 2025 business update conference call. At this time, all lines are in listen-only mode. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Matt Riley, Lucid Diagnostics Vice President of Investor Relations. Please go ahead.

Matt Riley
Lucid Diagnostics Inc - Director of Investor Relations

Thank you, operator, and good morning, everyone. Thank you for participating in today's business update call. Joining me today on the call are Dr. Lishan Aklog , Chairman and CEO of Lucid Diagnostics, along with Dennis McGrath, Chief Financial Officer. The press release announcing our business update and financial results is available on Lucid's website.

Please take a moment to read the disclaimers about forward-looking statements in the press release. The business update, press release, and conference call all include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot